Caris is scaling toward profit
- Q1 2026 revenue rose 78.8% year over year to $216.2 million.
- The net loss fell to $0.5 million, close to breakeven.
- MI Cancer Seek lifted the average selling price for MI Profile through higher reimbursement.
- Caris Assure cases rose to 9,200 in Q1 2026 from 5,800 a year earlier.
- The main worry is whether new tests can win payer support while R&D spending keeps rising.
Fast growth, thin cushion
Caris is showing real scaling power. In Q1 2026, revenue rose 78.8% year over year to $216.2 million, while the net loss narrowed to $0.5 million. That is a major change from the prior year period, when the net loss was $102.6 million.
The bull case is simple: more tests, better prices, and more data can feed each other. MI Profile remains the main engine. MI Cancer Seek, now part of MI Profile, helped raise the average selling price because it brought higher reimbursement. Caris Assure, the blood-based platform, is also growing from a smaller base.
The bear case is not gone. Caris still needs to spend on sales, research, and new products like Caris Detect. Management has said it may keep reporting net losses while it invests. The company also has to prove that payers will keep paying for newer tests at attractive rates.
The next big watch items are Caris Assure volume, the 2026 launch of whole genome sequencing solutions, and how Caris uses its financing agreement with Blue Owl Capital and Blackstone. That agreement gives up to $1.2 billion in debt capacity, with $400.0 million initially funded.
Tests first, data second
Caris makes most of its money by selling molecular profiling services. These tests read cancer samples from tissue or blood to help doctors pick treatments. In Q1 2026, molecular profiling services produced $210.8 million of revenue.
The second business sells pharma research and development services. Drug companies use Caris data, testing, and bioinformatics to study cancer and improve drug programs. In Q1 2026, this business produced $5.4 million of revenue.
The model can work well if test volumes rise and each test earns strong reimbursement. The risk is that payers, doctors, or drug companies decide the value is not high enough. If that happens, revenue growth and margins could slow fast.
A cancer testing stack
MI Profile
MI Profile is the tissue-based profiling platform and has generated most of Caris' revenue to date. Q1 2026 MI Profile cases reached 43,600, up from 40,100 a year earlier.
MI Cancer Seek
MI Cancer Seek is the WES and WTS next-generation sequencing component of MI Profile. Its launch raised the average selling price for MI Profile through higher reimbursement.
Caris Assure
Caris Assure is the blood-based profiling platform. Q1 2026 cases rose to 9,200 from 5,800 a year earlier, making it one of the clearest volume catalysts.
Precision Whole Genome Platform
Caris expects to launch whole genome sequencing solutions in 2026. This could broaden the test menu, but adoption and payment still need to be proven.
Caris Detect
Caris Detect is a future solution tied to broader cancer care, including early detection and monitoring. It could expand the market, but it will need validation, clinical use, and payer support.
Biopharma R&D services
Caris works with drug companies on testing, data, bioinformatics, and discovery projects. This business is smaller than clinical testing but can make the data platform more valuable.
Mostly clinical testing
The mix is from Q1 2026 revenue in the 10-Q. Molecular profiling is the clear revenue base, so any reimbursement change in that line matters a lot.
What could break
Reimbursement pressure
High impact · Medium oddsMI Cancer Seek helped lift the average selling price for MI Profile. That is good while payers support it. If reimbursement rates fall or coverage gets narrower, growth could slow even if test volume keeps rising.
Caris Assure adoption stalls
High impact · Medium oddsCaris Assure is a key growth product because it uses blood instead of tissue. Q1 2026 case volume rose to 9,200, but it still needs broader use by doctors and payers. If that curve flattens, the bull case loses a major leg.
Profit slips back into losses
Medium impact · Medium oddsCaris nearly reached breakeven in Q1 2026 with a $0.5 million net loss. But the company is still investing in research, sales, and future products. Management has warned that expenses may rise and net losses may continue in the near future.
New product execution risk
Medium impact · Medium oddsWhole genome sequencing solutions and Caris Detect could expand the company beyond current testing. They also require validation, clinical demand, regulatory progress where needed, and payer acceptance. A slow launch would reduce the value of the pipeline.
Debt-funded expansion misfires
Medium impact · Low oddsCaris has access to up to $1.2 billion in debt capacity, with $400.0 million initially funded. That gives it room to expand or buy assets. It also raises the cost of a bad deal if growth does not follow.
In one breath
What does Caris Life Sciences do?
Caris sells cancer molecular profiling tests. These tests study tumor tissue or blood so doctors can better match patients with treatments.
How does Caris make money?
Most revenue comes from molecular profiling services sold for clinical use. A smaller part comes from pharma research and development services, where drug companies use Caris testing, data, and bioinformatics.
Is Caris profitable?
Caris was close to breakeven in Q1 2026, with a $0.5 million net loss on $216.2 million of revenue. The company has shown much better operating leverage, but it may report losses again as it invests in new products.
What is the biggest catalyst for CAI stock?
The clearest near-term catalysts are rising Caris Assure case volume, sustained higher reimbursement from MI Cancer Seek, and the planned 2026 launch of whole genome sequencing solutions.